MTOR and acute lymphoblastic leukemia: Notably, CCI-779 (Temsirolimus), RAD001 (Everolimus) and the ATP-competitive mTOR inhibitor INK128 demonstrated anti-leukemic activity on ALL cell lines and primary samples [50–52].